Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 13/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14077694 | 0.90 | SLC16A1 (0.57) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| Azd3965 SCHEMBL5093552 | 0.89 | SLC16A1 (0.48) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| Azd3965 SCHEMBL2875156 | 0.89 | SLC16A1 (0.48) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5139201 | 0.84 | SLC16A1 (0.45) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5093405 | 0.81 | SLC16A1 (0.41) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5093462 | 0.80 | SLC16A1 (0.73) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5097036 | 0.79 | SLC16A1 (0.43) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5100191 | 0.79 | SLC16A1 (0.40) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5140584 | 0.79 | SLC16A1 (0.40) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5099873 | 0.79 | SLC16A1 (0.38) | SLC16A1CYP2C9CYP3A4SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116801906-A | Combination therapy for cancer | 阿雷斯贸易股份有限公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-4237001-A1 | COMBINATION TREATMENT OF CANCER | Ares Trading S.A. (CH) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022090527-A1 | COMBINATION TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2022-05-05 | — | — | WO | disclosed |